圣诺生物 (688117)
Cheng Du Sheng Nuo Biotec Co., Ltd.
K-Line Chart
No K-line data available
Company NameChengdu Shengnuo Biotechnology Co., Ltd.
Listing Date2021-06-03
Issue Price17.9RMB
Registered Capital11241.855610k RMB
Legal RepresentativeWen Yongjun
Registered AddressNo. 98 Da'an Road, Dayi County, Chengdu City, Sichuan Province, China
IndustryChemical Pharmaceuticals
Main BusinessProvides pharmaceutical research and customized production services for peptide-based innovative drug R&D of domestic and foreign pharmaceutical companies. Independently researches, develops, produces, and sells peptide-based generic drug active pharmaceutical ingredients (APIs) and finished dosage forms with significant market capacity and strong competitiveness both domestically and internationally, as well as technology transfer services for peptide drug production. Additionally, the company is engaged in the contract manufacturing of the small-molecule chemical drug levosimendan formulations and the production and export of levosimendan APIs.
Company ProfileChengdu Shengnuo Biotechnology Co., Ltd. possesses the Chengdu Municipal 'Chengdu Peptide Drug Engineering Technology Research Center'. We passed the US FDA certification with zero deficiencies and have now become a first-class domestic specialized peptide drug industrial park engaged in product development, technology transfer, technical services, large-scale production, and export. The company participated in the National 11th Five-Year Plan Major New Drug Development Project 'Research on Key Technologies for Peptide Chemical Modification and Industrial-Scale Preparation'. The National Innovation Fund for Technology-based SMEs grant project 'Novel Anti-Heart Failure Drug Nesiritide' undertaken by the company has entered the clinical research stage. In 2010, it received special funds for emerging industries from the Sichuan Provincial Economic Commission to conduct industrial achievement transformation research on peptide drugs. The aforementioned projects have all completed their construction objectives. The company has mastered the key technologies for large-scale production of over 50 marketed peptide drugs and products globally, with single-batch yields reaching kilogram levels. It possesses internationally leading technologies such as large-scale production technology for thio-cyclic peptides, large-scale production technology for carbocyclic peptides, complex peptide technology, and rapid peptide synthesis technology. The company has applied for 23 invention patents and has been granted 5 invention patents. With its robust key technologies in peptide synthesis and modification, it has become a leader in China's peptide industry.
Stock Details
1. Key Indicators
- Total Shares(W): No data
- Circulating A-Shares(W): No data
- Earnings Per Share(RMB): No data
- Net Assets Per Share(RMB): No data
- Operating Revenue(W RMB): No data
- Total Profit(W RMB): No data
- **Net Profit Attributable to Parent(W RMB) **: No data
- Net Profit Growth Rate(%): No data
- Weighted Return on Equity(%): No data
- Operating Cash Flow Per Share(RMB): No data
- Undistributed Profit Per Share(RMB): No data
- Capital Reserve Per Share(RMB): No data
2. Main Business
The main business covers:
- No data
3. Company Basic Information
- Company Name: No data
- Listing Date: No data
- Industry: No data
- Address: No data
- Website: No data
- Company Profile: No data
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Sichuan Sainuo Investment Co., Ltd. | Corporate Entity | 4782.40 | 30.39 |
| 2 | Sichuan Development Securities Investment Fund Management Co., Ltd. - Sichuan Capital Market Relief and Development Securities Investment Fund Partnership (Limited Partnership) | Asset Management Plan | 989.03 | 6.28 |
| 3 | Lepu Medical (Beijing) Co., Ltd. | Corporate Entity | 466.40 | 2.96 |
| 4 | Hainan Sheng Nuo Enterprise Management Center (Limited Partnership) | Corporate Entity | 465.50 | 2.96 |
| 5 | Huashang Intelligent Life Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 28.30 | 0.18 |
| 6 | Xinda Small and Medium Cap Mixed Securities Investment Fund Class A | Fund | 25.21 | 0.16 |
| 7 | Huashang Emerging Vitality Flexible Allocation Hybrid Securities Investment Fund | Fund | 13.00 | 0.08 |
| 8 | Huashang Core Growth One-Year Holding Period Hybrid Securities Investment Fund Class A | Fund | 11.00 | 0.07 |
| 9 | Huashang Excellent Growth One-Year Holding Period Hybrid Securities Investment Fund Class A | Fund | 8.00 | 0.05 |
| 10 | Furong Research Preferred Hybrid Securities Investment Fund Class A | Fund | 3.91 | 0.02 |
5. Concept Sectors
- No data
Remarks
- Data update date: 2025-09-30
- Data source: Public market information